Ermium Therapeutics strengthen its leadership team with the recent appointment of Dr Hélène Asnagli as head of biology / pharmacology
November 18, 2022
Ermium Therapeutics strengthen its leadership team with the recent appointment of Dr Hélène Asnagli as head of biology / pharmacology
Ermium Therapeutics SAS, a discovery-stage biotechnology company developing innovative therapies for auto-immune diseases, is announcing today the expansion of the Company management team with the appointment of Dr Hélène Asnagli as Head of Biology/Pharmacology.
Dr Asnagli brings strong expertise in non-clinical R&D for auto-immune diseases.